JP2009531051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531051A5 JP2009531051A5 JP2009502200A JP2009502200A JP2009531051A5 JP 2009531051 A5 JP2009531051 A5 JP 2009531051A5 JP 2009502200 A JP2009502200 A JP 2009502200A JP 2009502200 A JP2009502200 A JP 2009502200A JP 2009531051 A5 JP2009531051 A5 JP 2009531051A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- library
- drug
- level
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- -1 SCBGB2A2 Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 102100021761 Alpha-mannosidase 2 Human genes 0.000 claims 2
- 102100039239 Amidophosphoribosyltransferase Human genes 0.000 claims 2
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 claims 2
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 claims 2
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims 2
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims 2
- 101000615953 Homo sapiens Alpha-mannosidase 2 Proteins 0.000 claims 2
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 claims 2
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 claims 2
- 101001051207 Homo sapiens L-lactate dehydrogenase B chain Proteins 0.000 claims 2
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims 2
- 101001135344 Homo sapiens Polypyrimidine tract-binding protein 1 Proteins 0.000 claims 2
- 101001123146 Homo sapiens Serine/threonine-protein phosphatase 4 regulatory subunit 1 Proteins 0.000 claims 2
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 claims 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims 2
- 101150053046 MYD88 gene Proteins 0.000 claims 2
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims 2
- 102000002356 Nectin Human genes 0.000 claims 2
- 108060005251 Nectin Proteins 0.000 claims 2
- 102100033073 Polypyrimidine tract-binding protein 1 Human genes 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 102100028618 Serine/threonine-protein phosphatase 4 regulatory subunit 1 Human genes 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108010049285 dephospho-CoA kinase Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 108091005646 acetylated proteins Proteins 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 208000022602 disease susceptibility Diseases 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0606096.6 | 2006-03-27 | ||
| GBGB0606096.6A GB0606096D0 (en) | 2006-03-27 | 2006-03-27 | Screening method |
| PCT/GB2007/001086 WO2007110623A2 (en) | 2006-03-27 | 2007-03-27 | Screening method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013087048A Division JP6017367B2 (ja) | 2006-03-27 | 2013-04-18 | スクリーニング法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009531051A JP2009531051A (ja) | 2009-09-03 |
| JP2009531051A5 true JP2009531051A5 (enExample) | 2011-04-21 |
| JP5528103B2 JP5528103B2 (ja) | 2014-06-25 |
Family
ID=36384256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502200A Expired - Fee Related JP5528103B2 (ja) | 2006-03-27 | 2007-03-27 | スクリーニング法 |
| JP2013087048A Expired - Fee Related JP6017367B2 (ja) | 2006-03-27 | 2013-04-18 | スクリーニング法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013087048A Expired - Fee Related JP6017367B2 (ja) | 2006-03-27 | 2013-04-18 | スクリーニング法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8784806B2 (enExample) |
| EP (3) | EP2733491B1 (enExample) |
| JP (2) | JP5528103B2 (enExample) |
| AT (1) | ATE537445T1 (enExample) |
| DK (2) | DK2005162T3 (enExample) |
| ES (3) | ES2376912T3 (enExample) |
| GB (1) | GB0606096D0 (enExample) |
| WO (1) | WO2007110623A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1751115A4 (en) | 2004-05-23 | 2010-10-20 | Gerard M Housey | THERAMUTEINMODULATOREN |
| EP2502649A1 (en) | 2005-02-03 | 2012-09-26 | TopoTarget UK Limited | Combination therapy using HDAC inhibitors and erlotinib for treating cancer |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
| US8642809B2 (en) | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
| WO2014164775A1 (en) * | 2013-03-11 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Methods and compositions to improve the spread of chemical signals in plants |
| GB201306339D0 (en) * | 2013-04-08 | 2013-05-22 | Isis Innovation | Biomarkers for prognosis |
| GB2524519B (en) * | 2014-03-25 | 2019-11-06 | Pelago Bioscience AB | Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay |
| ES2702432B2 (es) | 2017-08-31 | 2019-08-05 | Venegas Pedro Manuel Medina | Método y dispositivo para el análisis de ácidos nucleicos |
| GB201914517D0 (en) * | 2019-10-08 | 2019-11-20 | Randox Laboratories Ltd | Xbp1 isoform multiplex assay |
| CA3258625A1 (en) * | 2022-07-27 | 2024-02-01 | E-Therapeutics Plc | ZPI INHIBITANT DOUBLE-STRANDED NUCLEIC ACID COMPOUNDS |
| CN116949169B (zh) * | 2023-07-31 | 2024-02-06 | 山东大学齐鲁医院 | Smek1在缺血性脑卒中诊治中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123896A1 (en) * | 2001-10-25 | 2005-06-09 | Benz Christopher C. | Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby |
| US20030186903A1 (en) * | 2001-11-23 | 2003-10-02 | Isis Pharmaceuticals Inc. | Antisense modulation of MyD88 expression |
| US20050118596A1 (en) | 2002-02-08 | 2005-06-02 | Asselbergs Fredericus Alphonsus M. | Method for screening for compounds having hdac inhibitory activity |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| BR0316737A (pt) | 2002-11-27 | 2005-12-13 | Irm Llc | Métodos e composições para induzir apoptose em células cancerosas |
| CA2519320A1 (en) * | 2003-02-19 | 2004-09-02 | Astellas Pharma Inc. | Method of estimating antitumor effect of histone deacetylase inhibitor |
| CA2535889A1 (en) * | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| GB0401876D0 (en) * | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| US8193332B2 (en) * | 2004-04-09 | 2012-06-05 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| CN1985007A (zh) * | 2004-04-15 | 2007-06-20 | 罗斯塔英法美蒂克斯有限责任公司 | 鉴定介导活细胞对药物响应的基因的方法 |
| WO2006020016A2 (en) * | 2004-07-19 | 2006-02-23 | Schering Corporation | Myd88 as a therapeutic target for cancer |
| CN102605066A (zh) * | 2004-12-08 | 2012-07-25 | 安万特药物公司 | 测量对多西他赛抗药性或敏感性的方法 |
| EP1996935B1 (en) * | 2006-02-23 | 2011-09-14 | Yale University | Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway |
| GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
-
2006
- 2006-03-27 GB GBGB0606096.6A patent/GB0606096D0/en not_active Ceased
-
2007
- 2007-03-27 AT AT07732147T patent/ATE537445T1/de active
- 2007-03-27 US US12/294,603 patent/US8784806B2/en active Active
- 2007-03-27 ES ES07732147T patent/ES2376912T3/es active Active
- 2007-03-27 JP JP2009502200A patent/JP5528103B2/ja not_active Expired - Fee Related
- 2007-03-27 DK DK07732147.9T patent/DK2005162T3/da active
- 2007-03-27 DK DK13194854.9T patent/DK2733491T3/en active
- 2007-03-27 EP EP13194854.9A patent/EP2733491B1/en not_active Not-in-force
- 2007-03-27 ES ES13194854.9T patent/ES2607753T3/es active Active
- 2007-03-27 ES ES11162743.6T patent/ES2569663T3/es active Active
- 2007-03-27 EP EP07732147A patent/EP2005162B1/en not_active Not-in-force
- 2007-03-27 EP EP11162743.6A patent/EP2365335B1/en not_active Not-in-force
- 2007-03-27 WO PCT/GB2007/001086 patent/WO2007110623A2/en not_active Ceased
-
2013
- 2013-04-18 JP JP2013087048A patent/JP6017367B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-16 US US14/306,137 patent/US9347103B2/en not_active Expired - Fee Related
-
2016
- 2016-04-29 US US15/143,435 patent/US10012652B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531051A5 (enExample) | ||
| Krueger et al. | A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis | |
| Sullivan et al. | Trisomy 21 consistently activates the interferon response | |
| US20200232045A1 (en) | Methods of identifying individuals at increased risk of lung cancer | |
| Adams et al. | Genetic determinants of micronucleus formation in vivo | |
| Adua et al. | Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer | |
| Wang et al. | Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein | |
| JP2012500389A5 (enExample) | ||
| WO2017165199A1 (en) | Next-generation biomarkers to detect sun damage and predict skin cancer risk | |
| Sun et al. | Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis | |
| JP2021106615A (ja) | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント | |
| Chorzalska et al. | Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia | |
| JP2011517932A5 (enExample) | ||
| JP2008537474A5 (enExample) | ||
| CN104975099A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| Bukhari et al. | PINTology: A short history of the lncRNA LINC‐PINT in different diseases | |
| Batchu et al. | Lung and kidney ACE2 and TMPRSS2 in renin-angiotensin system blocker–treated comorbid diabetic mice mimicking host factors that have been linked to severe COVID-19 | |
| Xu et al. | The deubiquitinating enzyme USP1 is auto-ubiquitinated and destabilized by ML323 in colorectal cancer cells | |
| JP2006505241A (ja) | Ｈｄａｃ阻害活性を有する化合物のスクリーニング法 | |
| Voic et al. | RNA sequencing identifies common pathways between cigarette smoke exposure and replicative senescence in human airway epithelia | |
| JP2012507268A5 (enExample) | ||
| JP2015505669A5 (enExample) | ||
| Zapater et al. | Micro-RNA in obstructive sleep apnoea: biomarker of cardiovascular outcome? | |
| WO2011137302A1 (en) | Methods for identifying aberrantly regulated intracellular signaling pathways in cancer cells | |
| CN107937520B (zh) | 与结直肠癌相关的分子标记物、抑制剂、试剂盒和药剂 |